German startup T-CURX secures €17.7 million to support development of new cancer treatments

Würzburg-based T-CURX today reveals the very first closing of a EUR17.7 million Collection A to increase scientific advancement of T-CURX non-viral scientific CAR-T treatments in AML and strong growth signs, along with progressing T-CURX exclusive non-viral innovations for in vivo CAR-T generation.

The Collection An organization was led by BiomedVC and consisted of Bayern Kapital, Emphasize Funding (HLC), and i & iBio Fund, as added capitalists in addition to existing and brand-new specific capitalists.

Ulf Grawunder, PhD, founder and chief executive officer of T-CURX, claims: “ I am extremely delighted that T-CURX drew in such a top-level, worldwide financier’s distribute, led by BiomedVC, for funding T-CURX’ s non-clinical and scientific CAR-T innovations and CAR-T pipe programs, specifically. It is a testimony of the excellent quality of T-CURX information and the assurance of our non-clinical and scientific non-viral CAR-T pipe in AML & CLL and strong growth signs pursuing unique targets. It additionally highlights the high worth of our distinct method to take advantage of non-viral CAR-vector and LNP innovations for very affordable and scalable in vivo CAR-T generation, in order to ‘democratise’ CAR-T treatments for clients worldwide“

In 2025, financing task indicate consistent however careful financial investment task throughout Europe’s oncology and immuno-oncology landscape, giving context for T-CURX’s Collection A.

Together With the German CAR-T programmer, numerous various other cancer-focused business have actually protected financing this year. In Switzerland, Hedera Dx increased EUR15 million in a Collection A to scale its accuracy oncology and diagnostics system focused on enhancing accessibility to targeted cancer cells treatments. Finland-based TILT Biotherapeutics protected EUR22.6 million in a Collection B to breakthrough scientific advancement of its immuno-oncology prospects for strong tumors, while Dutch start-up BIMINI Biotech shut a EUR3 million Seed round to proceed small-molecule treatments for haematological cancers cells.

Taken with each other, these rounds stand for about EUR58 million in revealed financing relocating with the European cancer cells and immunotherapy market in 2025. Within this mate, T-CURX’s Collection A rates amongst the bigger early-stage elevates and stands apart for its concentrate on non-viral CAR-T innovations created in Germany.

Aristotelis Nastos, PhD, Handling Companion and financial investment supervisor at lead-investor BiomedVC includes: “ I am delighted regarding leading an extremely specialized worldwide distribute of early-stage capitalists from Europe and Asia in this Collection A funding for T-CURX. We were deeply thrilled by the information on non-viral CAR-T item and modern technology advancement at T-CURX, the track-record and experience of T-CURX Owner’s and Administration group and the assurance of T-CURX non-viral CAR-T innovations hold for making CAR-T treatments obtainable and budget-friendly for numerous cancer cells clients worldwide.

” We are significantly anticipating sustain T-CURX to accomplish every one of their restorative and business aspirations.“

Established In 2017, T-CURX is a German BioTech business spun-out of the research laboratory of its founder, Prof. Michael Hudecek, College of Würzburg, that is a European KOL and leader in the advancement and scientific translation of non-viral CAR-T cell treatments to target numerous kinds of cancer cells.

Their goal is to bring next-generation CAR-T cell treatments made with affordable and very scalable non-viral CAR-T cell innovations to extra cancer cells clients seeking even more reliable cancer cells treatments.

T-CURX leverages a profile of exclusive non-viral CAR-T innovations for scalable and affordable CAR-T production based upon virus-free, Sleeping-beauty transposon genetics transfer right into person’s T cells.

The blog post German startup T-CURX secures €17.7 million to support development of new cancer treatments showed up initially on EU-Startups.